Study of EDB-102 for lung cancer with liver spread
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an investigational drug called EDB-102 for people with a specific type of advanced lung cancer (non-small cell lung cancer) that has spread to the liver. It is for patients whose cancer has stopped responding to a certain targeted therapy (like osimertinib). The study will check the safety of the drug and see if it helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced non-small cell lung cancer (NSCLC) that cannot be removed by surgery and has spread to the liver.
- Your cancer has a specific mutation called EGFR L858R, and you have taken a third-generation EGFR inhibitor (such as osimertinib) but your cancer progressed or you couldn't tolerate it.
- You have at least one liver tumor that can be biopsied and measured, and that tumor has the EGFR L858R mutation.
- You are willing to provide a fresh tissue sample from a liver tumor for testing.
- Your overall health is good (ECOG 0 or 1), and your blood, liver, and kidney function are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding OBI-833/OBI-821 to the standard targeted pill erlotinib works better for some people with EGFR-mutated lung cancer. It may help shrink tumors that already started responding to erlotinib.
This trial tests a new combination of two medications (SKB264 and anlotinib) for people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to a standard pill called an EGFR-TKI. The goal is to see if this combination can shrink tumors and help people live longer.
This study tests a new drug, ANS014004, combined with an EGFR-TKI (a targeted therapy) for people with advanced non-small cell lung cancer that has EGFR mutations. The aim is to see if the combination is safe and effective in slowing the cancer's growth.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This study tests whether using a blood test to detect leftover tumor DNA after surgery can guide extra treatment for people with EGFR-mutant lung cancer. The goal is to see if starting or avoiding targeted therapy based on this test improves outcomes.
This trial tests whether adding a new drug (SYS6010) to the standard targeted therapy osimertinib before surgery can help shrink EGFR-positive lung tumors more than osimertinib alone. It is for people with early-stage (II to IIIB) non-small cell lung cancer that can be removed surgically.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.